MALMÖ, Sweden--(BUSINESS WIRE)--Regulatory News:
Hansa Medical (STO:HMED):
Second quarter in brief
Business highlights
›› US Food and Drug Administration (FDA) cleared Hansa Medical’s IND application for a study with IdeS in kidney transplantation
Hansa Medical (STO:HMED):
Second quarter in brief
Business highlights
›› US Food and Drug Administration (FDA) cleared Hansa Medical’s IND application for a study with IdeS in kidney transplantation